The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s exhibiting significant efficacy in clinical trials for managing obesity. Unlike some available weight loss approaches, retatrutide appears to offer a significant substantia